PARADIGM: Amplatzer Valvular Plug for PVL Closure

PARADIGM PARAvalvular Leak Closure With the Amplatzer Valvular Plug occluDer for Interventional Transcatheter Closure for PVL With Surgical bioloGical and Mechanical Heart Valve


Lead Sponsor: Abbott Medical Devices

Source Abbott Medical Devices
Brief Summary

The Paradigm study is a prospective, multicenter, single arm study to demonstrate the safety and effectiveness of the AVP III as a treatment for clinically significant PVLs following surgical implant of a mechanical or biological heart valve implanted in the aortic or mitral position.

Detailed Description

PARADIGM is a prospective, international, multi-center, single arm study to demonstrate the safety and effectiveness of the AVP III for percutaneous, transcatheter closure of PVLs occurring after aortic or mitral valve replacement with a surgically-implanted mechanical or bioprosthetic valve. The study will be conducted at up to 25 clinical sites in the US, EU and Canada, where a total of 200 subjects with a clinically significant PVL will undergo an AVP III implant procedure for PVL closure. Pre-procedural Baseline and follow-up assessments at Discharge, 30 days, 6 months and 1 year will include echocardiography, physical examinations, lab measurements and questionnaires to assess PVL severity, prosthetic valve function, hemolytic anemia, heart failure symptoms, and quality of life. Adverse events will be recorded throughout the study.

Overall Status Enrolling by invitation
Start Date 2020-12-01
Completion Date 2023-12-01
Primary Completion Date 2023-12-01
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
Paravalvular leak closure success rate (percent of subjects) 30 Days
Enrollment 200

Intervention Type: Device

Intervention Name: Amplatzer Valvular Plug III

Description: Transcatheter closure of a paravalvular leak using Amplatzer Valvular Plug III

Arm Group Label: Paravalvular Leak Closure



Inclusion Criteria: - Subject is implanted with a mechanical or biological surgical valve in the aortic or mitral position - Note: Subjects in European countries can only be implanted with a mechanical valve in the aortic or mitral position - Subject has a clinically significant paravalvular leak with a severity grade of moderate or higher, associated with signs of heart failure and/or hemolysis necessitating recurring blood transfusions. - Subject has one clinically significant PVL defect that can be closed with a single AVP III as assessed pre-procedurally - Subject has provided written informed consent - Subject is ≥18 years old Exclusion Criteria: - Subject has a rocking valve or extreme dehiscence of the prosthetic valve involving more than 40% of the sewing ring - Subject's PVL(s) originates from a transcatheter aortic or mitral valve replacement, or from rapid deployment or sutureless surgical replacement valves - Subject has a prosthetic aortic valve and prosthetic mitral valve which both have a clinically significant paravalvular leak. - Subject who is hemodynamically unstable or who cannot undergo an elective procedure - Subject with active endocarditis or other active infection - Subject has within the last 6 months a previously documented intracardiac mass, vegetation, tumor, or thrombus which would interfere with placement of the AVP III - Subject has inadequate vasculature for delivery of the AVP III - Subject has unsuitable anatomy for PVL closure using the AVP III (such as a PVL associated with an abscess cavity or a pseudoaneurysmal sac) or anatomy where the AVP III would interfere with other intracardiac or intravascular structures (such coronary ostia) - Subjects who are unable to receive intraprocedural anticoagulant therapy - Pregnant or nursing subjects or subjects who plan pregnancy during the clinical investigation follow-up period. - Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results. - Life expectancy is less than 1 year in the opinion of the Investigator - Incapacitated individuals, defined as persons with mental illnesses or handicaps that impair their ability to provide informed consent, or individuals without legal authority to provide informed consent. - Individual who are currently participating in an investigational drug or device study that has not reached the primary endpoint or that may confound the results of this study



Minimum Age:

18 Years

Maximum Age:


Healthy Volunteers:


Overall Official
Last Name Role Affiliation
Carlos Ruiz, M.D., Ph.D Principal Investigator Hackensack Meridian Health
Ospedale San Raffaele | Milano, Italy
St. Antonius Ziekenhuis | Utrecht, Netherlands
Gornoslaskie Centrum Medyczne Leszka Gieca | Katowice, Poland
Hospital Ramón y Cajal | Madrid, 28034, Spain
Hospital Universitario de Salamanca | Salamanca, Spain
The Royal Sussex County Hospital | Brighton, United Kingdom
Location Countries





United Kingdom

Verification Date


Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: Paravalvular Leak Closure

Type: Experimental

Description: Includes all eligible subjects who undergo an AVP III implant attempt for treatment of significant paravalvular leakage with an echocardiographic severity grade of moderate or higher. This is a single arm study.

Patient Data No
Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

This information was retrieved directly from the website without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on, this will be updated automatically on our website as well.

Clinical Research News